Debate Continues Between Upfront Surgery and Neoadjuvant Chemo in Advanced Ovarian Cancer

R. Wendel Naumann, MD, discusses the criteria for primary debulking versus neoadjuvant chemotherapy in patients with advanced ovarian cancer.

More From BioPortfolio on "Debate Continues Between Upfront Surgery and Neoadjuvant Chemo in Advanced Ovarian Cancer"